Advertisement
A vs BIO
Which Stock Would AI Choose? Agilent Technologies (A) vs. Bio-Rad Laboratories (BIO) Stock Comparison
Key Takeaways
- Agilent Technologies (A) and Bio-Rad Laboratories (BIO) both operate in the life sciences and diagnostics sector, with A focused on analytical instruments and BIO emphasizing research tools and clinical diagnostics.
- Recent market activity shows both stocks posting strong gains, with A advancing over 11% in the past month amid raised full-year guidance and BIO rising approximately 19% over the same period following its Q2 results.
- A reported Q2 revenue growth of 10% year-over-year with an EPS beat and increased guidance, while BIO delivered Q2 adjusted EPS and revenue beats despite some Life Science segment headwinds.
- A carries an upcoming Q3 earnings catalyst on August 26, whereas BIO reported results earlier in August with a more cautious analyst target range.
- Sector exposure is similar, but A demonstrates higher recent momentum and operating margin expansion compared to BIO's mixed segment performance.
- Market sentiment remains constructive for both, though relative positioning favors consistency in growth execution for one over the other in current conditions.
Introduction
Agilent Technologies (A) and Bio-Rad Laboratories (BIO) represent two established players in the life sciences and healthcare equipment space, making them natural candidates for comparison among investors seeking exposure to analytical tools, diagnostics, and research instrumentation. Traders and portfolio managers focused on the healthcare sector often evaluate these names for their growth profiles, earnings visibility, and sensitivity to broader economic and research spending trends. This comparison highlights observable differences in recent performance, business drivers, and market positioning to assist in relative assessment without implying specific recommendations.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies provides analytical instruments, reagents, and software for life sciences, diagnostics, and applied chemical markets. In recent weeks, the stock has exhibited notable strength, climbing more than 11% over the past month and reaching levels near $159 following its Q2 2026 results. The company reported revenue of $1.835 billion, representing a 10% year-over-year increase, alongside a non-GAAP EPS beat and expanded operating margins. Management raised full-year revenue and EPS guidance, contributing to positive sentiment. With Q3 earnings scheduled for August 26, attention remains on execution consistency amid favorable analyst coverage.
Bio-Rad Laboratories (BIO) Overview and Recent Performance
Bio-Rad Laboratories develops and manufactures products for life science research and clinical diagnostics, including instruments for digital PCR and electrophoresis. Recent market activity has been positive, with the stock advancing around 19% over the past month to trade near $380 after reporting Q2 2026 results on August 4. The quarter featured adjusted EPS and revenue beats, supported by more than 20% growth in digital PCR instrument revenue, though the Life Science segment faced headwinds while EMEA showed recovery. Analyst sentiment reflects a hold bias with targets below recent trading levels, underscoring a measured outlook despite solid year-to-date gains exceeding 25%.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots drawn from hundreds available across the platform. These bots trade thousands of different tickers using varied strategies, timeframes, and risk parameters, yet only those demonstrating the strongest alignment with prevailing market conditions earn placement in the trending section. Performance statistics among active bots typically span wide ranges in win rates, average returns per trade, and drawdown profiles, reflecting diverse approaches from short-term momentum capture to longer-horizon trend following. All bots maintain distinct statistical profiles and ticker universes. Review the full Trending AI Robots collection to explore options suited to individual trading preferences.
Head-to-Head Comparison
Agilent Technologies (A) and Bio-Rad Laboratories (BIO) share life-sciences sector exposure yet differ in business emphasis, with A leaning toward applied analytical solutions and BIO toward specialized research and diagnostics tools. Recent momentum has favored A through guidance raises and margin expansion, while BIO delivered earnings beats offset by segment-specific pressures. Growth drivers for A include broad instrument demand, whereas BIO highlights targeted product lines such as digital PCR. Risk factors encompass macroeconomic sensitivity to research budgets for both, though A shows tighter recent trend consistency. Market sentiment appears more uniformly positive toward A’s near-term catalysts relative to BIO’s positioning.
Tickeron AI Verdict
Based on observable factors including stronger recent price momentum, guidance momentum, and an imminent earnings catalyst, Tickeron’s AI models would currently assign a higher probabilistic preference to Agilent Technologies (A) over Bio-Rad Laboratories (BIO) for trend consistency and relative positioning in the prevailing environment. This assessment remains probabilistic and subject to evolving data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and BIO is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green whileBIO’s FA Score has 2 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- BIO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 5 TA indicator(s) are bullish while BIO’s TA Score has 3 bullish TA indicator(s).
- A’s TA Score: 5 bullish, 4 bearish.
- BIO’s TA Score: 3 bullish, 3 bearish.
Price Growth
A (@Medical Specialties) experienced а +3.35% price change this week, while BIO (@Medical/Nursing Services) price change was +7.47% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +5.38%. For the same industry, the average monthly price growth was +16.48%, and the average quarterly price growth was +29.67%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.79%. For the same industry, the average monthly price growth was +10.41%, and the average quarterly price growth was -10.89%.
Reported Earning Dates
A is expected to report earnings on Aug 26, 2026.
BIO is expected to report earnings on Oct 22, 2026.
Industries' Descriptions
@Medical Specialties (+5.38% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (+0.79% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| A | BIO | A / BIO | |
| Capitalization | 43.3B | 10.1B | 429% |
| EBITDA | 1.96B | 440M | 446% |
| Gain YTD | 13.435 | 25.998 | 52% |
| P/E Ratio | 30.81 | 46.50 | 66% |
| Revenue | 7.23B | 2.59B | 279% |
| Total Cash | 1.81B | 1.57B | 115% |
| Total Debt | 3.36B | 1.38B | 243% |
A | BIO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 78 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 87 Overvalued | |
PROFIT vs RISK RATING 1..100 | 91 | 100 | |
SMR RATING 1..100 | 44 | 88 | |
PRICE GROWTH RATING 1..100 | 6 | 6 | |
P/E GROWTH RATING 1..100 | 39 | 10 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (10) in the Biotechnology industry is significantly better than the same rating for BIO (87) in the Medical Specialties industry. This means that A’s stock grew significantly faster than BIO’s over the last 12 months.
A's Profit vs Risk Rating (91) in the Biotechnology industry is in the same range as BIO (100) in the Medical Specialties industry. This means that A’s stock grew similarly to BIO’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for BIO (88) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than BIO’s over the last 12 months.
A's Price Growth Rating (6) in the Biotechnology industry is in the same range as BIO (6) in the Medical Specialties industry. This means that A’s stock grew similarly to BIO’s over the last 12 months.
BIO's P/E Growth Rating (10) in the Medical Specialties industry is in the same range as A (39) in the Biotechnology industry. This means that BIO’s stock grew similarly to A’s over the last 12 months.
| A | BIO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 70% | 2 days ago 67% |
| Stochastic ODDS (%) | 2 days ago 68% | N/A |
| Momentum ODDS (%) | 6 days ago 67% | N/A |
| MACD ODDS (%) | 2 days ago 64% | N/A |
| TrendWeek ODDS (%) | 2 days ago 62% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 60% | 2 days ago 68% |
| Advances ODDS (%) | 5 days ago 59% | 2 days ago 65% |
| Declines ODDS (%) | 8 days ago 64% | 8 days ago 69% |
| BollingerBands ODDS (%) | 2 days ago 68% | 2 days ago 81% |
| Aroon ODDS (%) | 2 days ago 63% | 2 days ago 63% |
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.